Evaxion Biotech A/S
Industry
- Digital Health
- Artificial Intelligence
- Pharmaceuticals
- Vaccines
- Biotechnology
- Drug Discovery Technologies
- Bioinformatics
- Drug Discovery Technologies
Latest on Evaxion Biotech A/S
Who: Evaxion/Merck & Co What: The US giant has bought an option to license two preclinical vaccine candidates for gonorrhea and an undisclosed bacterial infectious disease from the Danish biotech.
Alliances centered on artificial intelligence and machine learning (AI/ML) applications have become ubiquitous in the biopharmaceutical sector in recent years and are projected to accelerate. But a re
During the COVID-19 pandemic, the pharmaceutical industry, academia and health care providers rallied to rapidly create and deploy vaccines against the SARS‑CoV‑2 virus. While these efforts initially
Evaxion Biotech A/S , which is using its artificial intelligence-based technology platform to develop immunotherapies, has unveiled positive data on two of its vaccine candidates that the Danish firm